83 FR 21300 - National Institute on Drug Abuse; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 83, Issue 90 (May 9, 2018)
National Institutes of Health
Federal Register Volume 83, Issue 90 (May 9, 2018)
| Page Range | 21300-21300 | |
| FR Document | 2018-09900 |
[Federal Register Volume 83, Number 90 (Wednesday, May 9, 2018)] [Notices] [Page 21300] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-09900] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01-Clinical Trials Not Allowed). Date: June 6, 2018. Time: 12:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, hiromi.ono@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Improving Implementation of Seek, Test, Treat & Retain Strategies Among People Who Inject Drugs in Low to Middle Income Countries (R01-Clinical Trial Required). Date: June 14, 2018. Time: 12:00 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center. 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute onDrug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, hiromi.ono@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Identification of Genetic and Genomic Variants byNext-Gen Sequencing in Non-Human Animal Models (U01). Date: June 21, 2018. Time: 12:00 p.m. to 2:00 p.m. Agenda: To review and evaluate cooperative agreement applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, NationalInstitute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892-9550, 301-827-5819, gm145A@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: May 4, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018-09900 Filed 5-8-18; 8:45 am] BILLING CODE 4140-01-P
![21300 Federal Register / Vol. 83, No. 90 / Wednesday, May 9, 2018 / Notices
DEPARTMENT OF HEALTH AND previous year. We are unable to place Pathogenesis and Substance Abuse
HUMAN SERVICES international calls for public comments. Comorbidity (R01–Clinical Trials Not
To request a time slot for public Allowed).
Meeting of the Chronic Fatigue comments, please send an email to Date: June 6, 2018.
Syndrome Advisory Committee cfsac@hhs.gov by Wednesday, June 13, Time: 12:00 p.m. to 3:30 p.m.
2018. The email should contain the Agenda: To review and evaluate grant
AGENCY: Department of Health and applications.
speaker’s name and the telephone
Human Services, Office of the Secretary, Place: National Institutes of Health,
number that will be used for public
Office of the Assistant Secretary for Neuroscience Center, 6001 Executive
comments.
Health. Individuals who would like to Boulevard, Rockville, MD 20852, (Telephone
ACTION: Notice. provide written testimony to Committee Conference Call).
members should submit a copy of their Contact Person: Hiromi Ono, Ph.D.,
SUMMARY: As stipulated by the Federal Scientific Review Officer, Office of
Advisory Committee Act, the U.S. testimony prior to the meeting. It is
Extramural Policy and Review, National
Department of Health and Human preferred, but not required, that the
Institute on Drug Abuse, National Institutes
Services (HHS) is hereby giving notice submitted testimony be prepared in
of Health, DHHS, 6001 Executive Boulevard,
that a webinar meeting of the Chronic digital format and typed using a 12-
Room 4238, MSC 9550, Bethesda, MD 20892,
Fatigue Syndrome Advisory Committee pitch font. Copies of the written
301–827–5820, hiromi.ono@nih.gov.
(CFSAC) will take place and open to the testimony must not exceed 5 single-
space pages, and it is preferred, but not Name of Committee: National Institute on
public to listen in via a toll free number. Drug Abuse Special Emphasis Panel
required that the document be prepared
DATES: The CFSAC webinar will be held Improving Implementation of Seek, Test,
in the MS Word format. Please note that
on Wednesday, June 20, 2018, from 9:00 PDF files, handwritten notes, charts, Treat & Retain Strategies Among People Who
a.m. until 5:00 p.m. and on Thursday, Inject Drugs in Low to Middle Income
and photographs cannot be accepted.
June 21, 2018 from 9:00 a.m. to 5:00 Countries (R01–Clinical Trial Required).
Materials submitted should not include
p.m. (EST). Date: June 14, 2018.
sensitive personal information, such as Time: 12:00 p.m. to 2:30 p.m.
ADDRESSES: This meeting will be social security number, birthdates,
broadcasted to the public as a webinar. Agenda: To review and evaluate grant
driver’s license number, passport applications.
A webinar is a virtual meeting. number, financial account number, or a Place: National Institutes of Health,
Registration is not required for the credit or debit card number. If you wish Neuroscience Center. 6001 Executive
webinar. to remain anonymous, you must specify Boulevard, Rockville, MD 20852, (Telephone
FOR FURTHER INFORMATION CONTACT: this in the document. Conference Call).
Gustavo Ceinos, MPH, Designated The Committee welcomes input on Contact Person: Hiromi Ono, Ph.D.,
Federal Officer, Chronic Fatigue any topic related to ME/CFS. Scientific Review Officer, Office of
Syndrome Advisory Committee, Dated: April 27, 2018. Extramural Policy and Review, National
Department of Health and Human Gustavo Ceinos, Institute onDrug Abuse, National Institutes of
Services, 200 Independence Avenue Commander, USPHS, Designated Federal Health, DHHS, 6001 Executive Boulevard,
SW, Room 728F.6, Washington, DC Officer. Room 4238, MSC 9550, Bethesda, MD 20892,
20201. Please direct all inquiries to [FR Doc. 2018–09844 Filed 5–8–18; 8:45 am]
301–827–5820, hiromi.ono@nih.gov.
cfsac@hhs.gov. BILLING CODE 4150–42–P Name of Committee: National Institute on
SUPPLEMENTARY INFORMATION: The Drug Abuse Special Emphasis Panel
CFSAC is authorized in 42 U.S.C.217a, Identification of Genetic and Genomic
Section 222 of the Public Health Service DEPARTMENT OF HEALTH AND Variants byNext-Gen Sequencing in Non-
Act, as amended. The purpose of the HUMAN SERVICES Human Animal Models (U01).
CFSAC is to provide advice and Date: June 21, 2018.
National Institutes of Health Time: 12:00 p.m. to 2:00 p.m.
recommendations to the Secretary of
Agenda: To review and evaluate
Health and Human Services (HHS),
National Institute on Drug Abuse; cooperative agreement applications.
through the Assistant Secretary for
Notice of Closed Meetings Place: National Institutes of Health,
Health (ASH), on issues related to Neuroscience Center, 6001 Executive
myalgic encephalomyelitis/chronic Pursuant to section 10(d) of the Boulevard, Rockville, MD 20852, (Telephone
fatigue syndrome (ME/CFS). The issues Federal Advisory Committee Act, as Conference Call).
can include factors affecting access and amended, notice is hereby given of the Contact Person: Gerald L. McLaughlin,
care for persons with ME/CFS; the following meetings. Ph.D., Scientific Review Officer, Office of
science and definition of ME/CFS; and The meetings will be closed to the Extramural Policy and Review,
broader public health, clinical, research, public in accordance with the NationalInstitute on Drug Abuse, NIH,
and educational issues related to ME/ provisions set forth in sections DHHS, 6001 Executive Blvd., Room 4238,
CFS. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., MSC 9550, Bethesda, MD 20892–9550, 301–
The agenda for this meeting, call-in as amended. The grant applications and 827–5819, gm145A@nih.gov.
information and location will be posted the discussions could disclose (Catalogue of Federal Domestic Assistance
on the CFSAC website http:// confidential trade secrets or commercial Program Nos.: 93.279, Drug Abuse and
www.hhs.gov/ash/advisory-committees/ property such as patentable material, Addiction Research Programs, National
cfsac/meetings/index.html. and personal information concerning Institutes of Health, HHS)
amozie on DSK3GDR082PROD with NOTICES
A one hour of public comments via individuals associated with the grant
Dated: May 4, 2018.
telephone will be scheduled for the first applications, the disclosure of which
and second day of the webinar. would constitute a clearly unwarranted Natasha M. Copeland,
Individuals will have five minutes to invasion of personal privacy. Program Analyst, Office of Federal Advisory
present their comments. Priority will be Committee Policy.
Name of Committee: National Institute on
given to individuals who have not Drug Abuse Special Emphasis Panel [FR Doc. 2018–09900 Filed 5–8–18; 8:45 am]
provided public comments within the Identification of Biomarkers of HIV–1 BILLING CODE 4140–01–P
VerDate Sep<11>2014 17:39 May 08, 2018 Jkt 244001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\09MYN1.SGM 09MYN1](https://thefederalregister.org/doc/83_FR_21390/page/1.svg)
Document Created: 2018-05-09 03:17:50
Document Modified: 2018-05-09 03:17:50
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | June 6, 2018. | |
| FR Citation | 83 FR 21300 |
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR